Intuitive Surgical (ISRG) remains robust in investment discussions for its consistent growth and potential. With strong
Q2 2024 revenue and profit growth expected, analysts recommend adding ISRG to portfolios. Despite a recent downgrade suggesting stocks nearing fair value, Jim Cramer encourages buying.
Q1 2024 earning call transcripts and preliminary Q4 revenues reflect improvement Y/Y, hinting strong preliminary Q4 results. The company has announced the
launch of a new robotic system, expectedly instigating some market tumult due to its significance. The system secured FDA clearance, bolstering stock performance. Some investors speculate modest choppiness post-launch, but the general sentiment remains bullish, fueled by an analyst upgrade.
Robust Q4 earnings growth and
procedure expansion are notable, with an increase in
procedure volume forecast following a Q1 beat. However, whispers of potential competition from autonomous operations in the sphere of robotic surgery are evident. Additionally, the
da Vinci 5, Intuitive Surgical's next-generation system, is seeking FDA approval and potentially disrupting the market once more. Overall, ISRG remains a strong contender in the investment market backed by strong growth records and promising innovations.
Intuitive Surgical ISRG News Analytics from Thu, 19 Oct 2023 07:00:00 GMT to Fri, 12 Jul 2024 19:34:13 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 8
